High cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is a major culprit in the development of atherosclerotic cardiovascular diseases, including coronary heart disease (CHD) in the elderly. However, in China, the awareness, treatment, and control rates for dyslipidemia are alarmingly low, at 10.93%, 6.84%, and 3.53% respectively. This gap is partly due to a lack of proper management at the primary care level and patient reluctance to adhere to treatment. Misinformation about statins, such as their perceived toxicity and potential harm to the liver and kidneys, often leads patients to discontinue these medications, further complicating lipid management.
For elderly patients with CHD, effective lipid management is crucial. These individuals often have a higher burden of vascular plaques and a greater risk of acute cardiovascular events, making them "high-risk" or "very high-risk" populations. The target LDL-C levels for these patients should be less than 1.8 mmol/L or even 1.4 mmol/L, depending on their risk profile.
Statins, such as atorvastatin and rosuvastatin, are commonly used to manage dyslipidemia by inhibiting HMG-CoA reductase in the liver, thereby reducing the synthesis of cholesterol and lowering plasma LDL-C levels. However, monotherapy with statins, especially at moderate doses, often fails to achieve the desired LDL-C reduction, with reductions typically less than 50%. Higher doses of statins can increase the risk of adverse effects, making it challenging to reach the target LDL-C levels.
The introduction of cholesterol absorption inhibitors like sebimibe (brand name: Cesame) offers a new, effective option for combination therapy. The 2023 Chinese Guidelines for the Management of Dyslipidemia recommend considering the addition of cholesterol absorption inhibitors when LDL-C levels remain uncontrolled with statin therapy alone. Early combination therapy can significantly reduce the risk of cardiovascular events, especially in very high-risk patients.
Clinical studies, primarily conducted in Chinese populations, have demonstrated the efficacy and safety of sebimibe. When combined with statins, sebimibe 20 mg/day can further lower LDL-C levels by approximately 16% compared to statin monotherapy, with good safety and tolerability. Sebimibe has a high glucuronide conjugate conversion rate of 98-99%, which enhances its cholesterol absorption inhibition. Additionally, sebimibe reaches peak plasma concentration within 0.5 to 12 hours, providing faster onset of action and earlier benefits for patients.
Sebimibe also has a high hepatic and renal clearance rate of 93%, reducing the risk of drug accumulation in the body, particularly in elderly patients who may have impaired liver function. For these patients, no dose adjustment is necessary, ensuring long-term safety. Furthermore, the different excretion pathways of sebimibe and statins minimize the risk of drug interactions, making it a safer option for long-term use.
It is essential to emphasize that the choice of medication for elderly CHD patients should be individualized, taking into account factors such as age, liver and kidney function, comorbidities, and potential drug interactions. For those requiring intensive lipid-lowering therapy, the combination of statins and sebimibe provides a safe and effective option. However, all medication regimens should be prescribed under the guidance of a healthcare provider and complemented with lifestyle modifications to achieve the best outcomes.